Orally bioavailable nonpeptide vitronectin receptor antagonists containing 2-aminopyridine arginine mimetics

Bioorganic and Medicinal Chemistry Letters

Volumn 9, Issue 13, 1999, Pages 1801-1806

  Keenan, Richard M ^a   Miller, William H ^a   Barton, Linda S ^a   Bondinell, William E ^a   Cousins, Russell D ^a   Eppley, Daniel F ^a   Hwang, Shing Mei ^a   Kwon, Chet ^a   Lago, M Amparo ^a   Nguyen, Thomas T ^a   Smith, Brian R ^a   Uzinskas, Irene N ^a   Yuan, Catherine C K ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR ANTAGONIST;

ARTICLE; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ORAL DRUG ADMINISTRATION; STRUCTURE ANALYSIS;

ADMINISTRATION, ORAL; AMINOPYRIDINES; ANIMALS; ARGININE; BIOLOGICAL AVAILABILITY; DOGS; KINETICS; RATS; RECEPTORS, VITRONECTIN;

EID: 0033526909     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(99)00282-6     Document Type: Article

References (15)

1. 3, see: (a) Samanen, J.; Jonak, Z.; Rieman, D.; Yue, T.-L. Curr. Pharmaceut. Design 1997, 3, 545. (b) Haubner, R.; Finsinger, D.; Kessler, H. Angew. Chem. Int. Ed. Engl. 1997, 36, 1374. (c) Horton, M. A. Int. J. Biochem. Cell Biol. 1997, 29, 721.
2. 3, see: (a) Samanen, J.; Jonak, Z.; Rieman, D.; Yue, T.-L. Curr. Pharmaceut. Design 1997, 3, 545. (b) Haubner, R.; Finsinger, D.; Kessler, H. Angew. Chem. Int. Ed. Engl. 1997, 36, 1374. (c) Horton, M. A. Int. J. Biochem. Cell Biol. 1997, 29, 721.
3. 3, see: (a) Samanen, J.; Jonak, Z.; Rieman, D.; Yue, T.-L. Curr. Pharmaceut. Design 1997, 3, 545. (b) Haubner, R.; Finsinger, D.; Kessler, H. Angew. Chem. Int. Ed. Engl. 1997, 36, 1374. (c) Horton, M. A. Int. J. Biochem. Cell Biol. 1997, 29, 721.
4. 2. Keenan, R. M.; Miller, W. H.; Kwon, C.; Ali, F. E.; Callahan, J. F.; Calvo, R. R.; Hwang, S.-M.; Kopple, K. D.; Peishoff, C. E.; Samanen, J. M.; Wong, A. S.; Yuan, C.-K.; Huffman, W. F. J. Med. Chem. 1997, 40, 2289.
5. 3. Keenan, R. M.; Miller, W. H.; Lago, M. A.; Ali, F. E.; Bondinell, W. E.; Callahan, J. F.; Calvo, R. R.; Cousins, R. D.; Hwang, S.-M.; Jakas, D. R.; Ku, T. W.; Kwon, C.; Nguyen, T. T.; Reader, V. A.; Rieman, D. S.; Ross, S. T.; Takata, D. T.; Uzinskas, I. N.; Yuan, C. C. K.; Smith, B. R. Bioorg. Med. Chem. Lett. 1998, 8, 3165.
6. 4. Keenan, R. M.; Lago, M. A.; Miller, W. H.; Ali, F. E.; Cousins, R. D.; Hall, L. B.; Hwang, S.-M.; Jakas, D. R.; Kwon, C.; Louden, C.; Nguyen, T.; Ohlstein, E.; Rieman, D. S.; Ross, S. T.; Samanen, J. M.; Smith, B. R.; Stadel, J. M.; Takata, D. T.; Vickery, L.; Yuan, C. C. K.; Yue, T.-L. Bioorg. Med. Chem. Lett. 1998, 8, 3171.
7. 5. The 2-aminopyridine ring system has previously found utility as an arginine replacement in the discovery of novel thrombin inhibitors. See: (a) Misra, R. N.; Kelly, Y. F.; Brown, B. R.; Roberts, D. G. M.; Chong, S.; Seiler, S. M. Bioorg. Med. Chem. Lett. 1994, 4, 2165. (b) Feng, D.-M.; Gardell, S. J.; Lewis, S. D.; Bock, M. G.; Chem, Z.; Freidinger, R. M.; Naylor-Olsen, A. M.; Ramjit, H. G.; Woltmann, R.; Baskin, E. P.; Lynch, J. J.; Lucas, R.; Shafer, J. A.; Dancheck, K. B.; Chen, I-W.; Mao, S.-S.; Krueger, J. A.; Hare, T. R.; Mulichack, A. M.; Vacca, J. P. J. Med. Chem. 1997, 40, 3726.
8. 5. The 2-aminopyridine ring system has previously found utility as an arginine replacement in the discovery of novel thrombin inhibitors. See: (a) Misra, R. N.; Kelly, Y. F.; Brown, B. R.; Roberts, D. G. M.; Chong, S.; Seiler, S. M. Bioorg. Med. Chem. Lett. 1994, 4, 2165. (b) Feng, D.-M.; Gardell, S. J.; Lewis, S. D.; Bock, M. G.; Chem, Z.; Freidinger, R. M.; Naylor-Olsen, A. M.; Ramjit, H. G.; Woltmann, R.; Baskin, E. P.; Lynch, J. J.; Lucas, R.; Shafer, J. A.; Dancheck, K. B.; Chen, I-W.; Mao, S.-S.; Krueger, J. A.; Hare, T. R.; Mulichack, A. M.; Vacca, J. P. J. Med. Chem. 1997, 40, 3726.
9. 6. See Albert, A. in Physical Methods in Heterocyclic Chemistry; Katritzky, A. R., Ed.; Academic: NY, 1963, Vol. 1, pp 2-103.
10. i values represent the means of values determined in two to three separate experiments. Typical assay variability was ±10%. See Wong, A.; Hwang, S. M.; McDevitt, P.; McNulty, D.; Stadel, J. M.; Johanson, K. Mol. Pharm. 1996, 50, 529-537.
11. i values represent the means of values determined in two to three separate experiments. Typical assay variability was ±10%. See Ali, F. E.; Bennett, D. B.; Calvo, R. R.; Elliott, J. D.; Hwang, S.-M.; Ku, T. W.; Lago, M. A.; Nichols, A. J.; Romoff, T. T.; Shah, D. H.; Vasko, J. A.; Wong, A. S.; Yellin, T. O.; Yuan, C.-K.; Samanen, J. M. J. Med. Chem. 1994, 37, 769.
12. 3 antagonists has been reported. See Wityak, J.; Pitts, W. J.; Tobin, A. E.; Estrella, M. J.; Harlow, P. P.; Corjay, M. H.; Mousa, S. A.; Wexler, R. R.; Jadhay, P. K. Book of Abstracts, 215th ACS National Meeting, March 29-April 2, 1998, MEDI-088.
13. 10. Samanen, J. M. Annu. Rep. Med. Chem. 1996, 31, 91.
14. 11. Samanen, J. M.; Lee, C.-P.; Smith, P. L.; Bondinell, W. E.; Calvo, R. R.; Jakas, D. R.; Newlander, K. A.; Parker, M.; Uzinskas, I.; Yellin, T. O.; Nichols, A. J. Advanced Drug Delivery Rev. 1996, 23, 133.
15. 12. Pharmacokinetic parameters were determined using non-compartmental analysis of plasma concentration of test compound versus time data determined in two to three separate animals. Oral bioavailability was calculated from the dose-normalized i.v. and p.o. AUC values, where AUC is the area under the plasma concentration versus time curve. See: Gibaldi, M.; Perrier, D. Absorption kinetics and bioavailability. In Pharmacokinetics, 2nd ed.; Swarbrick, J., Ed.; Marcel Dekker: New York, 1982: Vol. 15, pp 145-198.